UNLIMITED TURBO LONG - GILEAD SCIENCES | Real-time Bid/Ask 12:54:36 24/06/2024 BST | ||
| 1.4 EUR / 1.43 EUR | +1.07% |
|
| Current month | +84.21% | ||
| 1 month | +30.84% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
| Date | Price | Change |
|---|---|---|
| 24/06/24 | 1.4 | 0.00% |
| 21/06/24 | 1.4 | +17.65% |
| 20/06/24 | 1.19 | +77.61% |
| 19/06/24 | 0.67 | -1.47% |
| 18/06/24 | 0.68 | -19.05% |
Delayed Quote Börse Stuttgart
Last update June 24, 2024 at 12:53 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | 
BNP Paribas
|
| WKN | PP2B85 |
| ISIN | DE000PP2B850 |
| Date issued | 30/11/2017 |
| Strike | 56.61 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.99 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.56 € |
|---|---|
| Lowest since issue | 0.46 € |
| Spread | 0.03 € |
| Spread % | 2.10% |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
70.67
USD
Average target price
82.89
USD
Spread / Average Target
+17.29%
- Stock Market
- Certificates
- Certificat
